With the gradual development of artificial intelligence in various fields, the author has made a series of reports on typical cases, investment and financing, and industrial layout in the AI+ medical and health fields at home and abroad, for reference by investors and entrepreneurs in the industry.

This article introduces readers to a San Francisco-based startup that applies deep learning to new drug research and development to reduce high R&D costs. It is one of the typical examples of applying artificial intelligence technology to the field of medical health.

Founded in June 2012, Atomwise is a company that uses supercomputers for drug discovery. The project aims to simulate pharmaceutical processes using supercomputers, AI and sophisticated algorithms to predict the effectiveness of new drugs while reducing R&D costs. The company is headquartered in San Francisco, USA.

Atomwise uses artificial intelligence to develop new drugs: cost is plunging hundreds of millions of dollars

Status: The successful development of a new drug consumes approximately $2.9 billion

According to a 2014 report by the Tufts Drug Development Research Center, a successful new drug will cost an average of about $2.585 billion, including about $1.395 billion in direct capital investment and about 1.1 billion in research and development failures. Indirect investment of $63 million. It is reported that the data of this report has increased by about 145% compared with 2003.

Atomwise uses artificial intelligence to develop new drugs: cost is plunging hundreds of millions of dollars

US drug development cost map from 1996 to 2013 (including the cost of successfully listed drugs and the cost of R&D failed drugs)

The report also pointed out that after a successful launch of a new drug, there will be an average investment of 312 million US dollars. Used for further evaluation studies, including validation of new indications, dosage forms, and dosages. Therefore, in the development cycle before and after the listing, a successful new drug may consume a total of 2.9 billion US dollars.

Tufts' analysis data comes from 106 R&D projects in 10 pharmaceutical companies. Pharmaceutical plants vary in size but are reasonably distributed, accounting for 35% of the world's top 50 pharmaceutical companies' sales and R&D investment.

Reagent Bottle

Reagent Bottle,Clear Reagent Bottle,Clear Glass Reagent Bottle,Pp Cap Reagent Bottle

Yancheng Rongtai Labware Co.,Ltd , https://www.shtestlab.com